The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction-Reference-Cited by-同舟云学术

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction

Published:2021-11-26 Issue: Volume:7 Page:
ISSN:2057-7559
Container-title:Cardiac Failure Review
language:en
Short-container-title:Card Fail Rev

Author:

Brownell Nicholas K¹^ORCID,Ziaeian Boback¹^ORCID,Fonarow Gregg C²^ORCID

Affiliation:

1. Division of Cardiology, University of California Los Angeles (UCLA), Los Angeles, CA, US

2. Division of Cardiology, University of California Los Angeles (UCLA), Los Angeles, CA, US; Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center, Los Angeles, CA, US

Abstract

There are gaps in the use of therapies that save lives and improve quality of life for patients with heart failure with reduced ejection fraction, both in the US and abroad. The evidence is clear that initiation and titration of guideline-directed medical therapy (GDMT) and comprehensive disease-modifying medical therapy (CDMMT) to maximally tolerated doses improves patient-focused outcomes, yet observational data suggest this does not happen. The purpose of this review is to describe the gap in the use of optimal treatment worldwide and discuss the benefits of newer heart failure therapies including angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors. It will also cover the efficacy and safety of such treatments and provide potential pathways for the initiation and rapid titration of GDMT/CDMMT.

Publisher

Radcliffe Group Ltd

Subject

General Medicine

Reference79 articles.

1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics — 2020 update: a report from the American Heart Association. Circulation 2020;141:e139–596. https://doi.org/10.1161/CIR.0000000000000757; PMID: 31992061.

2. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013;6:606–19. https://doi.org/10.1161/HHF.0b013e318291329a; PMID: 23616602.

3. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 2017;70:2476–86. https://doi.org/10.1016/j.jacc.2017.08.074; PMID: 29141781.

4. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000–2017: population based cohort study. BMJ 2019:364:l223. https://doi.org/10.1136/bmj.l223; PMID: 30760447.

5. Greene SJ, Butler J, Fonarow GC. Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure – optimizing therapy with the need for speed. JAMA Cardiol 2021;6:743–4. https://doi.org/10.1001/jamacardio.2021.0496; PMID: 33787823.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heart failure management guidelines: New recommendations and implementation;Journal of Cardiology;2024-02

2. The Veterans Affairs’ Dashboard Confessional: Vindication of the VA HF Dashboard;Journal of Cardiac Failure;2024-01

3. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America;Journal of Cardiac Failure;2023-10

4. Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review;Value in Health;2023-10

5. Hospitalization for heart failure requires a PROMPT response;European Heart Journal;2023-09-06